Munemoto Y, et al. - In this prospective clinical trial, researchers assessed the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) intolerant to oxaliplatin and irinotecan. Also, screening was carried out for potential serum biomarkers to predict early therapeutic responses. In this patient population, it was safe to administer fluorouracil monotherapy combined with panitumumab. Serum lactase dehydrogenase levels may predict early responses.